Brentuximab [BRE8]
Re-use of brentuximab in relapsed/refractory Hodgkin lymphoma CHILD patients:
- An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
- The patient has relapsed or refractory CD30+ Hodgkin lymphoma.
- The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant
- Previous use of brentuximab achieved a partial/complete response to brentuximab
- Brentuximab is being used as a bridge to allogeneic stem cell transplantation or donor lymphocyte infusion
- Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response
- The patient is a child* and is either post pubescent or is pre pubescent and will receive brentuximab dosage described in the phase 2 part of the brentuximab trial protocol C25002 http://www.clinicaltrials.gov/ct2/show/NCT01492088?term=C25002&rank=1 and reported on http://www.bloodjournal.org/content/122/21/4378 in *note there is a separate Bluteq form to be used for brentuximab in this indication in adults.
- The use of the brentuximab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.
- No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process
- A maximum of 16 cycles of brentuximab will be administered to the patient when combining this reuse and previous cycles of brentuximab
- Trust policy regarding unlicensed treatments has been followed as brentuximab is not licensed in this indication in children.
- Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).
NHS funded From: 26 September 2017
Additional information
Form version:
CDF Managed Access: NA
NICE Technology Appraisal: TA524 (formerly TA446) (13 June 2018)
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.